Drug duo shows promise against hard-to-treat cancers
NCT ID NCT03085225
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times
Summary
This early-phase trial tested a combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find the safest dose and check for early signs of tumor shrinkage. The study is complete, and results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Bergonié
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.